GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the third quarter ended 30th September 2011. While the Company has posted an overall Sales growth of 4 percent compared to the previous quarter, the core pharmaceuticals business grew by 7 percent in this quarter.
Commenting on the performance, Dr Hasit B. Joshipura, Managing Director, said, Vaccine & Speciality franchises continue to register strong double digit growth which includes Dermatology, Oncology, Cardiovascular & Metabolic. The Mass Market businesses and Anti-Infectives were impacted by a relatively lower growth of the market and a high base effect. The ramp up in field force during the course of the year has impacted costs.
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world’s leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com.